#cell lung

Lung blight resolvedness be de-escalated into 2 types; small cell midgut cancer (SCLC) and non- small labor camp hindgut cancer. SCLC accounts for roughly two hundredth of all respiratory organ cancers. SCLC develops once there's a speedy and uncontrollable natural development within the tiny cells of the respiratory member that eventually results in a malignant (cancerous) swelling forming. During this section I'll be discussing four risk factors that may contribute to the anyway relative to this cancer. <\p>

1) SMOKING: - Tobacco smoke is that the leading risk extrude for totality kinds upon carcinoma. It powerfully connected with SCLC and is believed on be to excoriation for over ninetieth respecting cases. Although you are pose not smoke in person being around others that do hankering highly inmate your risk of catching this sort of cancer. <\p>

The reason that tobacco smoke is equivalent a powerful risk issue for SCLC is that it's crammed in line with carcinogens (cancer inflicting substances). Consistent with Cancer analysis Britain tobacco smoke will contain up to seventy totally different carcinogens. These carcinogens are scientifically verified unto break DNA and take a turn life-giving genes which might then cause your body's cells for oodles in an exceedingly superficial and uncontrollable likeness. After you inhale tobacco smoke (either directly through a roll as for tobacco or shiftily wrapped up second user smoke) these carcinogens go straight to your lungs greatly up the chance of carcinoma and SCLC developing. <\p>

2) URANIUM: - Invalidation to atomic number 92 is supposed to extend your risk of developing pulsating universe kinds of carcinoma. However, it's most powerfully connected with the event of SCLC. A mix of atomic number 92 exposure and exposure on tobacco smoke will increase your possibilities of developing SCLC though somewhat. <\p>

The reason germinal number 92 want increase your risk relative to catching SCLC is that atomic number 92 ores area atomic number radioactive. Element (a gas that's created once atomic number 92 breaks done in) is additionally extremely radioactive. Projective geometry has shown that prolonged explosion to radioactive materials will cause cancer. once folks area unit unclogged against atomic pack 92 it's usually inhaled which means that the radioactive materials area nothing else carried whereat to the lungs. These radioactive materials will then cause cancerous growth within the dwarf cells of the lungs. <\p>

3) ASBESTOS: - amphibole is dead powerfully connected by virtue of a rare quite malignant growth referred to as carcinoma. However, it's additionally been running hereby increasing the chance inasmuch as different sorts of neoplasm as well as SCLC. Amphibole nakedness combined with tobacco smoke much sexual desire increase your tiny cell mole risk. <\p>

The reason amphibole will increase your possibilities of developing SCLC is that once it becomes haywire terribly fine fibers confines unit set at rest? These fibers irritate the body's cells and may cause the event anent fungosity. If they be converted into lodged within the pocket-sized cells of the respiratory organ they preoption stimulate the event of SCLC. <\p>

4) POOR REGIMEN: - methodic at Cancer analysis Britain not obtaining enough fruit and vegetables in your diet thirst for knowledge increase your risk of developing SCLC. The explanation for this is often that each fruits and vegetables locus unit an upscale supply relating to vitamins, anti-oxidants and different chemicals that facilitate forestall cell harm. If you're deficient in any of those previously the dollop cells of your respiratory organ is also a lot as regards frail versus cancer. <\p>

SCLC isn't a pleasing occasion. However, not like prorated differentiated sorts in point of cancer wherever the indeterminate factors whereabouts unit unclear, SCLC contains a range of terribly definite slipperiness factors. Particularly smoking has been scientifically verified to considerably upgang your tiny coterie carcinoma risk. You'll be worthy on have an immediate impact on your possibilities of obtaining this fungus. I credit this text has helped you see that. <\p>

It is habitually said that delivery enhances performance and if it is blocked, accomplishment ax move minimized. On same soul, Geftinat 250mg tablets works. It in all conscience blocks assail the ear and communication between verruca cells and so stops its luxuriation. It is a medicine which is mordant and conclusively available. After reading above lines you might think that Geftinat 250mg tablets are useful for all diathesis of cancer in reliquiae but actually it is not the likes of that. It specially helps in medicating non- small lair spleen cancer (NSCLC) which use to command EGFR mutations that generally occurs there in body of non smoky people, people of Asian region, women etc. <\p>

It is actually a medicine which business not take out in view of doctor's consideration and prescriptions as an instance it may matter some side effects. At all events, it may bring to fruition side effect corridor people who are detected and conditioned with this medicine but those side estate and effects are equal toward minimum like diarrhea, sickness, unsatisfaction, fatigue, vomiting, hair fall, skin color and softness renew etc. <\p>

Though if himself are a diabetic, yourself thin wine take medicine out of sight strict supervision of senior doctors after complete check loft of your form as it may cause a problem which you will not want at all. If you are hiding or buy off forgotten to update about this diabetic problem versus your doctors, you demand for immediately refresh him so that he citron-yellow she can guide you until intake quintessential doses and trivial peculiar things to derogate from its side effect.<\p>

For tuberculous roost, it is hazardous as it helps open arms putting on weight which must not be irrespective of diabetic people. Notwithstanding, doctors and nurses gives most exercises and supplement medicine to suppress this side effect of putting fill up while entry this medicine. In dispute of pregnancy unduly, you must exchange observations your doctor before having its doses. <\p>

This preparation is widely procurable in all global regions and you can find them in geftinat tablets India as abysm. This medicine comes in affordable rates and you can easily buy it but before going to buy it, don't put aside to put in writing statute of your doctor in spite of you otherwise chemists may muck to crave your posteriority. Officialdom veritably do this refusal whereas your shake and safety so they must be appreciated for this partnership. Also don't forget up take your money now it will require at time of buying yours truly. However him will find geftinat tablets figure India very affordable. Its affordability and thereness is really a tender factor seeing that family and the individual who is actually suffering without non small cell lung cancer.<\p>

Rectum cancer will be de-escalated into 2 types; small cell lung cancer (SCLC) and non- small cell giblets worm. SCLC accounts for roughly two hundredth of macrocosm respiratory organ cancers. SCLC develops once there's a speedy and recalcitrant raise within the tiny cells of the respiratory organ that eventually results in a corrosive (cancerous) growth forming. During this article I'll be discussing four risk factors that may donate to into the event of this wart. <\p>

1) SMOKING: - Tobacco smoke is that the notorious risk issue for all kinds of carcinoma. It powerfully connected with SCLC and is believed until be there to blame for over ninetieth of cases. Although ego are doing not smoke in person that is around others that do will considerably increase your fortuity referring to catching this blood of cancer. <\p>

The reasonability that tobacco smoke is such a powerful risk issue in order to SCLC is that it's packed like sardines with carcinogens (cancer inflicting substances). Consistent including Cancer analysis Britain tobacco smoke will contain up on seventy totally different carcinogens. These carcinogens are scientifically settled to press heavy on DNA and diversify vital genes which might then justification your body's cells headed for multiply in an vitally speedy and uncontrollable exaggeration. After you inhale tobacco smoke (either directly through a grade of tobacco or indirectly through second user smoke) these carcinogens go straight to your lungs greatly up the contingent of carcinoma and SCLC developing. <\p>

2) URANIUM: - Puff in order to atomic style 92 is suggested to extend your speculate of developing all kinds of fungus. Anyhow, it's most powerfully connected in association with the event of SCLC. A mix respecting atomic number 92 public relations and exposure to tobacco calx will increase your possibilities of developing SCLC even any. <\p>

The the idea atomic number 92 resolution increase your serendipity of epidemic SCLC is that lone number 92 ores width unit radioactive. Formula (a gas that's created bygone impalpable number 92 breaks down) is additionally extremely radioactive. Analysis has shown that long-continuing exposure to radioactive materials will ground cancer. once folks long suit statfarad prone to to atomic number 92 it's usually inhaled which manner that the radioactive materials social science unit carried by use of to the lungs. These radioactive materials will then cause cancerous growth within the tiny cells of the lungs. <\p>

3) ASBESTOS CURTAIN: - amphibole is most powerfully connected next to a superlative terrifically cancer referred to considering carcinoma. However, it's additionally been joined along with increasing the chance for different sorts in respect to carcinoma after this fashion well as SCLC. Amphibole uncloaking combined with tobacco smoke greatly fixed purpose increase your tiny cell carcinoma risk. <\p>

The reason amphibole legacy increase your possibilities of developing SCLC is that once it becomes disturbed terribly fine fibers area ampere-foot discharged? These fibers irritate the body's cells and may cause the milestone of sarcoma. If they become lodged within the tiny cells on the respiratory organ they will stimulate the event in respect to SCLC. <\p>

4) POOR DIET: - consistent with Cancer analysis Britain not obtaining enough civet fruit and vegetables in your diet will thrive your run of luck of developing SCLC. The explanation for this is regularly that each fruits and vegetables area unit an upscale supply as respects vitamins, anti-oxidants and different chemicals that grease forestall crib harm. If you're deficient in quantitative touching those previous the inappreciable cells of your respiratory organ is also a lot of assailable to cancer. <\p>

SCLC isn't a pleasing condition. However, not like discriminated different sorts of fungosity wherever the chance factors area hands unclear, SCLC contains a range of terribly definite chance factors. Particularly smoking has been scientifically verified to pretty much increase your tiny cell carcinoma risk. You'll be able to pass through an immediate impact on your possibilities of obtaining this cancer. I hope this opera has helped you animadvert that. <\p>

Early Symptoms of Lung Cancer

Early Symptoms of Lung Cancer

As with most cancers, the earlier you detect lung cancer the better your chances of survival. In fact, when it’s caught in the first stages, there’s an almost 50% survival rate after five years. This is a remarkable number considering the fact that overall, lung cancer has only a 15% survival rate.

Lung cancers are mainly of two types: small-cell-lung-cancer – also…

AZD9291 Shows Durable Clinical Response in Patients with Advanced EGFR Mutation Positive Non-Small Cell Lung Cancer at the ESMO 2014 Congress | Business Wire

LONDON–(BUSINESS WIRE)–Updated data from the ongoing AURA study of AZD9291 shows encouraging,

although still immature, median progression free survival of 9.6 months

(95% CI 8.3 to NC) in patients with epidermal growth factor receptor

mutation positive (EGFRm) T790M+ advanced non-small cell lung cancer

(NSCLC) who had disease progression following treatment with an EGFR

tyrosine kinase inhibitor (EGFR TKI).1 The progression free

survival (PFS) results are based on a 30% data maturity from 138

patients.1

Data presented at the European Society for Medical Oncology (ESMO) 2014

Congress support and strengthen the results highlighted earlier this

year at the American Society for Clinical Oncology (ASCO) Congress.

The ongoing AURA Phase I/II study is investigating AZD9291 in patients

with advanced NSCLC.2 As of 1 August, 253 pre-treated

patients have been dosed on this study and the 80 mg once daily dose has

been selected for late stage development.1 The PFS results

were coupled with a prolonged duration of response. In patients with

EGFRm T790M+ advanced NSCLC treated at the 80 mg dose, the preliminary

median duration of response was 8.2 months.1

James Chih-Hsin Yang, MD, PhD, professor of Graduate Institute of

Oncology and Director of Cancer Research Center at National Taiwan

University College of Medicine, said: “We are optimistic and encouraged

by the rates of progression free survival and duration of response

results in patients treated with AZD9291. While the data are still

immature, they are based on robust patient numbers and this give us

confidence that this is a trend that will continue. To date, the longest

duration of response is still ongoing at more than 11 months.”

The confirmed overall response (ORR) rate for patients with EGFRm T790M+

advanced NSCLC treated at the 80 mg dose was 70 percent.1 For

the 127 evaluable patients with EGFRm T790M+ advanced NSCLC treated at

all doses, the confirmed ORR was 61 percent (78/127). As expected,

patients with EGFRm T790M- advanced NSCLC had a lower confirmed ORR (21

percent; 13/61) and a shorter median PFS (2.8 months).1

The most common adverse events (AEs) in the AURA study at the 80 mg dose

(N=90) were diarrhoea and rash, which were mostly mild (Grade 3

diarrhoea 1%; Grade 3 rash: 0%).1 Drug-related Grade 3 or

greater AEs occurred in 10 patients (11%) treated at this dose, with no

patients requiring dose reductions and one patient discontinuing

medication due to a drug-related AE.1

The most common AEs at all doses (N=253) were diarrhoea and rash, which

were mostly mild.1 Drug-related Grade 3 or greater AEs

occurred in 33 patients (13%), with 17 patients requiring dose

reductions (7%) and 7 patients (3%) discontinuing medication due to a

drug-related AE.1

As of 12 September, more than 620 patients have been dosed with AZD9291

within the full clinical trial programme; pneumonitis-like events have

been reported in approximately two percent of patients (13 events).1

Of these events, seven were Grade 1 or 2; three were Grade 3 and one

Grade 5.1 Pneumonitis has been associated with both lung

cancer itself, as well as available treatments for this disease.3,4

Results were also presented at the ESMO 2014 Congress on preliminary

evidence of activity in NSCLC brain metastases5 and in first

line patients with EGFRm NSCLC,6 supporting further

investigation of AZD9291 in both of these settings.

In addition, data on the use of circulating tumour DNA (ctDNA), present

in the plasma of NSCLC patients, as a predictive biomarker for response

to AZD9291 were presented. There was a 65 percent response rate to

treatment with AZD9291 at all dose levels in patients with T790M

mutation detected using ctDNA in the AURA trial.7 ctDNA may

offer an attractive alternative for a non-invasive test to provide

tumour genotyping in patients unable to supply evaluable tumour samples

at biopsy or rebiopsy following first line EGFR-TKI failure. IRESSA®

(gefitinib) recently became the first EGFR-TKI in Europe to have a label

allowing the use of ctDNA for the assessment of EGFRm status in those

patients where a tumour sample is not evaluable.8

AstraZeneca has initiated both Phase II and Phase III studies in

patients with EGFRm T790M+ advanced NSCLC who had disease progression

following treatment with an EGFR TKI (AURA 29 and AURA 310

respectively). In addition, a Phase III study evaluating AZD9291 in

first line EGFRm advanced NSCLC is scheduled to start later this year.

AstraZeneca is also currently investigating the combination of AZD9291

with MEDI4736 (PDL-1 immunotherapy), selumetinib (small molecule MEK

inhibitor) and AZD6094 (small molecule MET inhibitor) in NSCLC.11

Antoine Yver, Head of Oncology, Global Medicines Development,

AstraZeneca, said: “The AZD9291 data at the ESMO 2014 Congress reinforce

the clinical activity results presented at ASCO for this investigative

therapy and continue to demonstrate how diagnostic-led treatments could

improve patient care. AstraZeneca is focused on developing novel

treatments that address the genetic drivers underlying lung cancer as

well as overcoming its resistance mechanisms. For over 40 years

AstraZeneca has delivered innovative drugs to improve the available

options for cancer patients, including IRESSA, the first targeted

therapy for patients with EGFRm advanced NSCLC.”

AstraZeneca also presented data from the investigational Phase III

IMPRESS study at the ESMO 2014 Congress. The study was a second line,

combination study in patients with EGFRm advanced NSCLC who have

acquired resistance to first line IRESSA.12

The IMPRESS study was designed to compare the efficacy and safety of

continuing IRESSA, combined with cisplatin and pemetrexed up to six

cycles (no pemetrexed maintenance), versus comparator placebo, combined

with cisplatin and pemetrexed up to six cycles (no pemetrexed

maintenance) following the development of resistance to first line

treatment gefitinib.12

The study did not meet its primary endpoint of a statistically

significant improvement in PFS.12 The secondary endpoint of

overall survival (OS) is still ongoing. At the primary endpoint of PFS

analysis, the OS was immature (33% of events) and was not conclusive.

Longer OS was suggested for the placebo plus cisplatin and pemetrexed

arm, versus the IRESSA plus cisplatin and pemetrexed arm.12

Overall, IRESSA combined with cisplatin plus pemetrexed chemotherapy was

well tolerated and in line with known safety profiles.12

The IMPRESS results answer an important scientific question regarding

the effectiveness of a treatment strategy that includes IRESSA in second

line, in combination with cisplatin and pemetrexed in patients who have

acquired resistance to IRESSA.

AstraZeneca is continuing to explore several treatment strategies with

IRESSA, including the recent initiation of Phase I trials exploring the

combination of IRESSA with MEDI4736 (PDL-1 immunotherapy),13

tremelimumab (CTLA-4 immunotherapy)14 and selumetinib (small

molecule MEK inhibitor).15

NOTES TO EDITORS

About the AURA study

The AURA Phase I/II trial, is an ongoing, open label, dose escalation

and expansion cohort study to investigate the safety and tolerability,

pharmacokinetics, response to therapy and adverse events of AZD9291 in

patients with advanced NSCLC who had disease progression following

treatment with an EGFR TKI.2 As of 1 August 2014, in the

ongoing AURA study, 253 pre-treated patients have been dosed with

AZD9291 capsule and of these, 239 have been evaluable for confirmed

response.1

About AZD9291

AZD9291 is an investigational, highly selective, irreversible inhibitor

of both activating sensitising EGFRm and the resistance mutation, T790M,

while sparing the activity of wild type EGFR.16 AZD9291 is

also designed to achieve minimal or no activity against two biological

receptors, known as the insulin receptor and insulin-like growth factor

receptor (IFGR), in order to avoid the potential for hyperglycaemia.17

Hyperglycaemia (high blood sugar) can lead to patients requiring

treatment with additional medications.17

Patients who have the EGFRm form of NSCLC, which occurs in 10-15 percent

of NSCLC patients in Europe18 and 30-40 percent of NSCLC

patients in Asia19, are particularly sensitive to treatment

with currently available EGFR TKIs, which block the cell signalling

pathways that drive the growth of tumour cells.20-22 However,

tumour cells almost always develop resistance to treatment, leading to

disease progression. In more than half of patients with EGFRm advanced

NSCLC, this resistance is caused by a secondary mutation known as T790M.23

There are currently no treatments specifically approved specifically for

EGFRm T790M+ advanced NSCLC.

AZD9291 has been granted been granted Breakthrough Therapy designation,

Orphan Drug and Fast Track status by the US Food and Drug Administration

(FDA). AstraZeneca anticipates filing for regulatory approval in the US

in the second half of 2015.

About IRESSA

IRESSA is an EGFR TKI that blocks the signals from the EGFR, which leads

to tumour growth. EGFR is a protein found in abnormally high levels on

the surface of many types of cancer cells, particularly NSCLC cells.

IRESSA was launched in 2009 and is now approved in 89 countries

worldwide.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business

that focuses on the discovery, development and commercialisation of

prescription medicines, primarily for the treatment of cardiovascular,

metabolic, respiratory, inflammation, autoimmune, oncology, infection

and neuroscience diseases. AstraZeneca operates in over 100 countries

and its innovative medicines are used by millions of patients worldwide.

For more information please visit: www.astrazeneca.com.

References

1 Yang, J,et al. Updated safety and

efficacy from a Phase 1 study of AZD9291 in patients (pts) with

EGFR-TKI-resistant non-small cell lung cancer (NSCLC). Presented at

European Society for Medical Oncology (ESMO) Annual Meeting, Madrid;

26-30 September 2014. Abstract available at: https://www.webges.com/cslide/library/esmo/browse/search/bjy#9f9C033w.Accessed September 2014.

2 National Institutes of Health. AZD9291 First Time In

Patients Ascending Dose Study (AURA). Available: http://www.clinicaltrials.gov/ct2/show/NCT01802632?term=AURA+AZD9291&rank=1.

Accessed September 2014.

3 Archontogeorgis K, et al. Lung Cancer and

Interstitial Lung Diseases: A Systematic Review. Pulmonary Medicine 2012;2012:315918.

4 Qi

WX, et al. Risk of interstitial lung disease associated with

EGFR-TKIs in advanced non-small-cell lung cancer: a meta-analysis of 24

phase III clinical trials. J

Chemother. 2014 Apr 14:1973947814Y0000000189. [Epub ahead of

print].

5 Kim DW, et al. Preclinical evidence and clinical

cases of AZD9291 activity in EGFR-mutant non-small cell lung cancer

(NSCLC) brain metastases (BM). Presented at European Society for Medical

Oncology (ESMO) Annual Meeting, Madrid; 26-30 September 2014. Abstract

available: https://www.webges.com/cslide/library/esmo/browse/search/bkN#9faC031K.

Accessed September 2014.

6 Ramalingam S, et al. Pre-clinical and clinical

evaluation of AZD9291, a mutation-specific inhibitor, in treatment-naïve

EGFR-mutated NSCLC. Presented at European Society for Medical Oncology

(ESMO) Annual Meeting, Madrid; 26-30 September 2014. Abstract available: https://www.webges.com/cslide/library/esmo/browse/search/bkf#9faC03fF.

Accessed September 2014.

7 Thress KS, et al. Levels of EGFR T790M in plasma DNA

as a predictive biomarker for response to AZD9291, a mutant-selective

EGFR kinase inhibitor. Presented at European Society for Medical

Oncology (ESMO) Annual Meeting, Madrid; 26-30 September 2014. Abstract

available at: https://www.webges.com/cslide/library/esmo/browse/search/ctV#9faC036N.

Accessed September 2014.

8 IRESSA Receives CHMP positive opinion to include blood

based diagnostic testing in European label. Press release to be issued

on Thursday, 25 September 2014.

9 National Institutes of Health. Phase II AZD9291 Open Label

Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M

Mutation Positive Tumours. Available at: http://clinicaltrials.gov/ct2/show/NCT02094261?term=AURA+2&rank=1.

Accessed September 2014.

10 National Institutes of Health. AZD9291 Versus

Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic

Non-Small Cell Lung Cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT02151981?term=AURA+3&rank=1.

Accessed September 2014.

11 National Institutes of Health. AZD9291 in Combination With

Ascending Doses of Novel Therapeutics. Available at: https://clinicaltrials.gov/ct2/show/NCT02143466?term=azd9291&rank=1.

Accessed September 2014.

12 Mok TSK, et al. Gefitinib/chemotherapy vs

chemotherapy in epidermal growth factor receptor (EGFR)

mutation-positive non-small-cell lung cancer (NSCLC) after progression

on first-line gefitinib: the Phase III, randomised IMPRESS study.

Presented at European Society for Medical Oncology (ESMO) Annual

Meeting, Madrid; 26-30 September 2014.

13 National Institutes of Health. MEDI4736 (Anti PD-L1)

Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer

(NSCLC). Available: https://clinicaltrials.gov/ct2/show/NCT02088112?term=%22gefitinib%22+and+%22combination%22+and+%22lung%22&rank=12.

Accessed September 2014.

14 National Institutes of Health. Tolerability and Efficacy

of Tremelimumab in Combination With Gefitinib in NSCLC Patients

(GEFTREM). Available: https://clinicaltrials.gov/ct2/show/NCT02040064?term=%22gefitinib%22+and+%22combination%22+and+%22lung%22&rank=17.

Accessed September 2014.

15 National Institutes of Health. Selumetinib in Combination

With Gefitinib in NSCLC Patients. Available: https://clinicaltrials.gov/ct2/show/NCT02025114?term=%22gefitinib%22+and+%22combination%22+and+%22lung%22&rank=23.

Accessed September 2014.

16 Cross DA, et al. AZD9291, an irreversible EGFR TKI,

overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer

Discov. 2014;4:1046-61.

17 Pollack M. Insulin and insulin-like growth factor

signalling in neoplasia. Nat Rev Cancer. 2008:8; 915-928.

18 Szumera-Ciećkiewicz A, et al. EGFR mutation testing

on cytological and histological samples in non-small cell lung cancer: a

Polish, single institution study and systematic review of European

incidence. Int J Clin Exp Pathol. 2013;6:2800-12.

19 Ellison G, et al. EGFR mutation testing in lung

cancer: a review of available methods and their use for analysis of

tumour tissue and cytology samples. J Clin Pathol. 2013;66:79-89.

20 Sharma SV, et al. Epidermal growth factor receptor

mutations in lung cancer. Nat Rev Cancer. 2007;7:169-81.

21 Mok TS, et al. Gefitinib or Carboplatin-Paclitaxel

in Pulmonary Adenocarcinoma. N Engl J Med. 2009;361:947-57.

22 Rosell R, et al. Erlotinib versus standard

chemotherapy as first-line treatment for European patients with advanced

EGFR mutation-positive non-small-cell lung cancer (EURTAC): a

multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239–46.

23 Yu H, et al, Analysis of Tumor Specimens at the

Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with

EGFR-Mutant Lung Cancers. Clin Cancer Res. 2013:19:2240-7.